Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Chloroquine AND (Coronavirus 2019 OR COVID-19 OR SARS-CoV-2))
1,187 results
  • FDA Emergency Use Authorization: Glass Half Empty? [Journal Article]
    Clin Infect Dis. 2020 Oct 26 [Online ahead of print]Guharoy R, Krenzelok EP
  • Recently, the Food and Drug Administration (FDA) issued emergency use authorization (EUA) of convalescent plasma (CP) for the treatment of COVID-19 hospitalized patients based on a non-peer reviewed open label observational study. Issuance of an EUA without a proven randomized control trial (RCT) sets a dangerous precedent since the premature action drives health care providers and patients away …
  • The development of a quarantine strategy is an important path to a normalized response to COVID-19. [Journal Article]
    Biosci Trends. 2020 Oct 25 [Online ahead of print]Zhu H, Lu H
  • The ongoing pandemic of coronavirus disease 19 (COVID-19) is still in a global pandemic that has affected more than 200 countries. When prevention and control of COVID-19 is gradually normalized, communication between countries needs to be gradually restored due to development needs. There are 34 vaccines in the clinical evaluation stage and 145 vaccines in the preclinical evaluation stage in the…
  • Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. [Review]
    Intervirology. 2020 Oct 23 [Online ahead of print]Ortega JT, Zambrano JL, … Pujol FH
  • CONCLUSIONS: This review focused on the basic principles of virology and pharmacology to understand the importance of early stages of virus-cell interaction as therapeutic targets and other main processes vital for SARS-CoV-2 replication. Furthermore, we focused on describing the main targets associated with SARS-CoV-2 antiviral therapy and the rationale of drug combinations for efficiently suppressing viral replication. Key Messages: We hypothesized that blocking of both entry mechanisms could allow a more effective antiviral effect compared to the partial results obtained with chloroquine or its derivatives alone. This approach, already used to achieve an antiviral effect higher than that offered by every single drug administered separately, has been successfully applied in several viral infections such as HIV and HCV. This review will contribute to expanding the perception of the possible therapeutic targets in SARS-CoV-2 infection and highlight the benefits of using combination therapies.
  • COVID-19 therapy and prevention. [Review]
    Discoveries (Craiova). 2020 Sep 10; 8(3):e113.Claude-Rosny E
  • Since the outbreak of the new coronavirus pneumonia (COVID-19) in December 2019, more than 23 million people worldwide have been diagnosed with SARS-CoV-2. In response to this pandemic, a global mobilization of scientific, industrial and political support has ensued. However, more than 8 months later, as studies multiply and several governments are embarking on a resumption of their activities, t…
  • MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. [Journal Article]
    Brief Bioinform. 2020 Oct 20 [Online ahead of print]Feng Z, Chen M, … Xie XQ
  • Given the scale and rapid spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or 2019-nCoV), there is an urgent need to identify therapeutics that are effective against COVID-19 before vaccines are available. Since the current rate of SARS-CoV-2 knowledge acquisition via traditional research methods is not sufficient to match th…
  • Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. [Journal Article]
    Indian J Pharmacol. 2020 Jul-Aug; 52(4):313-323.Bhattacharyya A, Kumar S, … Medhi B
  • CONCLUSIONS: In our study, no difference was seen between the L/R combination and the SOC arm in terms of "progression to more severe state," "mortality," and virological cure on days 7-10;" however, some benefits in terms of "duration of hospital stay" and "time to virological cure" were seen. No significant difference in efficacy was seen when L/R was compared to arbidol and HCQ monotherapy. Except for the occurrence of diarrhea, which was higher in the L/R group, safety profile of L/R is comparable to SOC. Compared to L/R combination, CQ, L/R + arbidol, L/R + IFN-α, and L/R + IFN-1β showed better efficacy, but the external validity of these findings is limited by limited number of studies (1 study each).
  • Repurposing of drugs for Covid-19: a systematic review and meta-analysis. [Journal Article]
    Panminerva Med. 2020 Oct 19 [Online ahead of print]Kotecha P, Light A, … Elhage O
  • CONCLUSIONS: Due to the paucity in evidence, it is difficult to establish the efficacy of these drugs in the treatment of Covid-19 as currently there is no significant clinical effectiveness of the repurposed drugs. Further large clinical trials are required to achieve more reliable findings. A risk-benefit analysis is required on an individual basis to weigh out the potential improvement in clinical outcome and viral load reduction compared to the risks of the adverse events.
  • Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. [Review]
    Am J Emerg Med. 2020 Jul 19 [Online ahead of print]Della Porta A, Bornstein K, … Parris MA
  • CONCLUSIONS: Chloroquine and hydroxychloroquine are aminoquinoline derivatives widely used in the treatment of rheumatologic diseases including systemic lupus erythematosus and rheumatoid arthritis as well as for malaria prophylaxis. In early 2020, anecdotal reports and preliminary data suggested utility of hydroxychloroquine in attenuating viral loads and symptoms in patients with SARS-CoV-2 infection. Aminoquinoline drugs pose unique and significant toxicological risks, both during their intended use as well as in unsupervised settings by laypersons. The therapeutic range for chloroquine is narrow. Acute severe toxicity is associated with 10-30% mortality owing to a combination of direct cardiovascular effects and electrolyte derangements with resultant dysrhythmias. Treatment in the ED is focused on decontamination, stabilization of cardiac dysrhythmias, hemodynamic support, electrolyte correction, and seizure prevention.An understanding of the pathophysiology of acute chloroquine and hydroxychloroquine toxicity and available emergency treatments can assist emergency clinicians in reducing the immediate morbidity and mortality associated with this disease.
  • Outcomes of persons with COVID-19 in hospitals with and without standard treatment with (Hydroxy)chloroquine. [Journal Article]
    Clin Microbiol Infect. 2020 Oct 14 [Online ahead of print]Peters EJG, Collard D, … CovidPredict Study Group
  • CONCLUSIONS: After adjustment for confounders, mortality was not significantly different in hospitals that routinely treated patients with (hydroxy)chloroquine, compared with hospitals that did not. We compared outcomes of hospital strategies rather than outcomes of individual patients to reduce the chance of indication bias. This study adds evidence against the use of (hydroxy)chloroquine in hospitalised patients with COVID-19.
  • Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. [Review]
    Drugs. 2020 Oct 17 [Online ahead of print]Cantini F, Goletti D, … Foti R
  • CONCLUSIONS: Beyond the supportive therapy, up to now the best therapeutic approach for COVID-19 may be a three-step combination therapy, including remdesivir 100 mg/day (200 mg loading dose on first day) in the first stage of the disease, and combined dexamethasone 6 mg/day plus baricitinib 4 mg/day to target the immune dysregulation triggered by the SARS-CoV-2 infection. The promising results of anakinra should be confirmed by the ongoing RCTs.
New Search Next